Xilio Therapeutics (XLO) Change in Account Payables (2020 - 2026)

Xilio Therapeutics has reported Change in Account Payables for 7 years, with the latest figure at -$1.7 million in Q1 2026.

• Quarterly Change in Account Payables fell 184.75% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$938000.0 (down 175.58% YoY) and the FY2025 annual result came in at $152000.0, down 90.04% from the prior year.
• Change in Account Payables eased to -$1.7 million in Q1 2026 per XLO's latest filing, from $428000.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $2.1 million in Q2 2025 and troughed at -$1.8 million in Q3 2025.
• A 5-year average of -$92941.2 and a median of -$305000.0 in 2024 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2024 and 2025: Change in Account Payables soared 465.75% in 2024, then tumbled 542.14% in 2025.
• Over 5 years, Change in Account Payables stood at $1.5 million in 2022, then plunged by 130.06% to -$438000.0 in 2023, then jumped by 465.75% to $1.6 million in 2024, then plunged by 73.28% to $428000.0 in 2025, then plunged by 492.52% to -$1.7 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$1.7 million, $428000.0, and -$1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.